Shaanxi Meibang Pharmaceutical Group Co., Ltd.
605033.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -128.88 | -1.37 | -0.04 | -1.16 |
| FCF Yield | 7.57% | -5.42% | -6.77% | 8.49% |
| EV / EBITDA | -3,888.57 | 1,754.87 | 62.39 | -106.78 |
| Quality | ||||
| ROIC | 0.02% | 0.42% | 2.15% | -0.70% |
| Gross Margin | 34.32% | 32.05% | 33.59% | 23.32% |
| Cash Conversion Ratio | 4,794.41 | -16.86 | -3.62 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 3.91% | 4.05% | 4.11% | -0.82% |
| Free Cash Flow Growth | 255.56% | 9.50% | -217.07% | -23.01% |
| Safety | ||||
| Net Debt / EBITDA | 76.98 | -20.77 | -4.71 | 14.62 |
| Interest Coverage | -125.97 | 0.00 | 453.88 | -224.00 |
| Efficiency | ||||
| Inventory Turnover | 0.45 | 0.89 | 0.85 | 0.76 |
| Cash Conversion Cycle | 190.97 | 69.82 | -4.61 | 8.95 |